Research Analysts Set Expectations for Genelux Q1 Earnings

Genelux Corporation (NASDAQ:GNLX) – Research analysts at Brookline Capital Management increased their Q1 2026 earnings estimates for shares of Genelux in a research note issued to investors on Monday, January 12th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($0.17) per share for the quarter, up from their previous forecast of ($0.20). The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($0.69) EPS.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02.

Several other equities analysts have also recently issued reports on GNLX. Wall Street Zen cut Genelux from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a research note on Wednesday, October 8th. HC Wainwright reissued a “buy” rating on shares of Genelux in a report on Monday, January 5th. Lake Street Capital started coverage on Genelux in a report on Tuesday, October 21st. They set a “buy” rating and a $16.00 price target for the company. Finally, Maxim Group set a $20.00 price objective on shares of Genelux in a research report on Tuesday, October 21st. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Genelux Stock Performance

Shares of GNLX opened at $2.56 on Wednesday. Genelux has a fifty-two week low of $1.99 and a fifty-two week high of $8.53. The firm has a 50-day simple moving average of $4.45 and a 200-day simple moving average of $4.36. The company has a market capitalization of $97.41 million, a price-to-earnings ratio of -2.91 and a beta of 0.17.

Insider Activity at Genelux

In related news, Director John Thomas sold 10,000 shares of Genelux stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $5.00, for a total value of $50,000.00. Following the sale, the director directly owned 492,784 shares in the company, valued at $2,463,920. The trade was a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 15,990 shares of company stock valued at $82,054. 8.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. purchased a new stake in shares of Genelux during the 1st quarter worth $239,000. Flputnam Investment Management Co. increased its holdings in shares of Genelux by 708.1% in the 3rd quarter. Flputnam Investment Management Co. now owns 300,290 shares of the company’s stock valued at $1,261,000 after purchasing an additional 263,131 shares in the last quarter. Woodward Diversified Capital LLC lifted its stake in shares of Genelux by 21.7% in the second quarter. Woodward Diversified Capital LLC now owns 1,778,286 shares of the company’s stock valued at $5,104,000 after purchasing an additional 317,173 shares during the period. Global Retirement Partners LLC acquired a new stake in shares of Genelux in the second quarter valued at about $656,000. Finally, MAI Capital Management boosted its holdings in Genelux by 66,161.3% during the second quarter. MAI Capital Management now owns 236,553 shares of the company’s stock worth $679,000 after buying an additional 236,196 shares in the last quarter. Hedge funds and other institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.